Intellia Therapeutics (NASDAQ:NTLA) Downgraded by Wall Street Zen to “Sell”

Intellia Therapeutics (NASDAQ:NTLA) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Sunday.

A number of other equities research analysts have also recently commented on NTLA. Citizens Jmp reduced their price target on shares of Intellia Therapeutics from $29.00 to $21.00 and set a “market outperform” rating for the company in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. Sanford C. Bernstein set a $14.50 price target on Intellia Therapeutics in a research note on Tuesday, October 28th. HC Wainwright cut their price target on Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Finally, Oppenheimer set a $27.00 price objective on Intellia Therapeutics in a report on Friday, November 7th. Eleven investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $18.43.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $9.00 on Friday. Intellia Therapeutics has a fifty-two week low of $5.90 and a fifty-two week high of $28.25. The stock has a 50 day simple moving average of $16.13 and a two-hundred day simple moving average of $12.55. The company has a market cap of $1.04 billion, a P/E ratio of -2.11 and a beta of 2.44.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.02) by $0.10. The firm had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The company’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.34) EPS. On average, research analysts predict that Intellia Therapeutics will post -5.07 earnings per share for the current year.

Insider Buying and Selling

In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the transaction, the chief accounting officer owned 55,266 shares of the company’s stock, valued at $960,523.08. This trade represents a 3.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 3.10% of the company’s stock.

Institutional Trading of Intellia Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Headlands Technologies LLC bought a new stake in Intellia Therapeutics during the second quarter worth $26,000. Blue Bell Private Wealth Management LLC purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter valued at $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $30,000. Whipplewood Advisors LLC boosted its holdings in shares of Intellia Therapeutics by 114,900.0% in the 2nd quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after buying an additional 3,447 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its position in Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after buying an additional 1,655 shares during the period. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.